Clinical trials: Osler Rendu Disease
Hereditary Hemorrhagic Telangiectasia (HHT), Osler Weber Rendu Disease
Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT)
This is a 2-part study evaluating ATV-1601 in participants with moderate to severe HHT. Part 1 is a randomized, double-blind, placebo-controlled study evaluating 3 dosing regimens of ATV-1601.
- Trial name
- NCT07601425
- Testing
- ATV-1601
- Where
- 6 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Atavistik Bio, Inc
Vascular Anomaly, Osler Rendu Disease
Pregnancy in Women With Rare Multisystemic Vascular Diseases: COGRare5 Study
There are no prospective studies of pregnancies for the diseases studied here in (Heredity Hemorrhagic Telangiectasia, Marfan syndrome or related, primary lower limb lymphedema, superficial arteriovenous malformations, and…
- Conditions
- Vascular Anomaly, Osler Rendu Disease, Marfan Syndrome or Related, Lymphedema Primary
- Trial name
- COGRare5 (NCT04194619)
- Testing
- Questionnaire
- Where
- 37 sites in France
- Volunteers
- 400 people
- Sponsor
- Hospices Civils de Lyon
Hereditary Hemorrhagic Telangiectasia (HHT), Rendu Osler Disease
IV Bevacizumab Treatment of Patients With Hereditary Hemorrhagic Telangiectasia (HHT) or Rendu-Osler (RO) Disease: A Retrospective Analysis of French Cohort Data From 2009 to 2024
Rendu-Osler disease (RO), also known as Hereditary Haemorrhagic Telangiectasia (HHT), is an autosomal dominant genetic disorder. Its pathophysiology is associated with an imbalance in angiogenic balance.
- Trial name
- CoBé (NCT07772050)
- Testing
- Real World data study.
- Where
- France
- Volunteers
- 244 people
- Sponsor
- Hospices Civils de Lyon
Hereditary Hemorrhagic Telangiectasia, Rendu Osler Disease
Prospective Study of Antiplatelet and Anticoagulation Therapy in Hereditary Haemorrhagic Telangiectasia
The goal of this clinical trial is to evaluate in real life, in patients with Hereditary Hemorrhagic Telangiectasia (HHT), the tolerance of the strategy of use of anticoagulant and/or antiplatelet, by comparing a new exposure…
- Trial name
- PROPLACO-Tel (NCT05641142)
- Testing
- monitoring the use of anticoagulant and/or antiplatelet therapy in patients with osler rendering disease
- Where
- 18 sites in France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Clermont-Ferrand
Hereditary Hemorrhagic Telangiectasia, Osler Weber Rendu Disease
Propranolol for Epistaxis in Hereditary Hemorrhagic Telangiectasia Patients
Hereditary Hemorrhagic Telangiectasia (HHT) is a genetic disorder of angiogenesis associated with disabling epistaxis. Management of these nose bleedings requires more effective treatment.
- Trial name
- EPERO (NCT04113187)
- Testing
- Propranolol treatment
- Where
- France
- Volunteers
- 15 people
- Sponsor
- University Hospital, Bordeaux
Hereditary Hemorrhagic Telangiectasia, Rendu Osler Disease
Stress-Echography in Hereditary Haemorrhagic Telangiectasia Patient With Hepatic Involvement
The hepatic involvement of HHT (Hereditary Haemorrhagic Telangiectasia) disease is characterised by the formation of arterio-sus-hepatic shunts which lead to dilatation of the hepatic artery and may result in high output heart…
- Trial name
- ROSE (NCT05954481)
- Testing
- Stress echocardiography
- Where
- 2 sites in France
- Volunteers
- 47 people
- Sponsor
- Hospices Civils de Lyon
Telangiectasia, Hereditary Hemorrhagic, Rendu Osler Disease
Diagnostic Value of Ultra-low Dose Thoracic Scanner for the Pulmonary Arteriovenous Malformation Detection in HHT Patient
Hereditary hemorrhagic telangiectasia (HHT) is linked to a dysregulation of angiogenesis leading to the formation of arteriovenous malformations (AVM): cutaneo-mucous telangiectasia and visceral shunts.
- Trial name
- ULD OSLER (NCT04108052)
- Testing
- Low CT scanner without injection dose, Ultra-low dose CT scanner without injection
- Where
- France
- Volunteers
- 45 people
- Sponsor
- Hospices Civils de Lyon
Telangiectasia, Hereditary Hemorrhagic, Osler Rendu Disease
Efficacy of a Timolol Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) - (TEMPO)
Timolol is a nonselective β-blocker commonly used in the treatment of glaucoma. Recently it has been used topically for the treatment of superficial hemangiomas.
- Trial name
- TEMPO (NCT02484716)
- Testing
- Timolol nasal spray
- Where
- France
- Volunteers
- 58 people
- Sponsor
- Hospices Civils de Lyon
Rendu Osler Disease, Telangiectasia, Hereditary Hemorrhagic
BABH Study: Efficacy and Safety of Bevacizumab on Severe Bleedings Associated With Hemorrhagic Hereditary Telangiectasia (HHT).
The recognized manifestations of HHT are all due to abnormalities of vascular structure. Epistaxis and digestive arteriovenous malformations may be responsible for severe hemorrhages in 5% of HHT patients, requiring repeated…
- Trial name
- BABH (NCT03227263)
- Testing
- Bevacizumab, sodium chloride 0.9%
- Where
- 4 sites in France
- Volunteers
- 24 people
- Sponsor
- Hospices Civils de Lyon
Telangiectasia, Hereditary Hemorrhagic, Rendu Osler Disease
Efficacy of Nintedanib Per os as a Treatment for Epistaxis in HHT Disease.
The recognized manifestations of HHT are all due to abnormalities in vascular structure. Epistaxis are spontaneous, very variable, may occur as often as several times every day, and are recurrent in 90% of patients and associated…
- Trial name
- EPICURE (NCT03954782)
- Testing
- Nintedanib 150 mg and 100 mg soft capsules
- Where
- 8 sites in France
- Volunteers
- 61 people
- Sponsor
- Hospices Civils de Lyon
Hereditary Hemorrhagic Telangiectasia, HHT
Genotype-phenotype Association in Hereditary Hemorrhagic Telangiectasia
The present project aims to study the inflammatory and endothelial responses involved in the differences in clinical events related to both genotypes (ENG vs. ACVRL1) in HHT.
- Conditions
- Hereditary Hemorrhagic Telangiectasia, HHT, Rendu Osler Weber Disease
- Trial name
- Generate-HHT (NCT05550376)
- Testing
- Registry
- Where
- Spain
- Volunteers
- 85 people
- Sponsor
- Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Vascular Liver Disease, Portal Vein Thrombosis
Vienna Vascular Liver Disease Study
The aim of this Register Trial is to systematically study the epidemiology, risk factors, liver function as well prognosis of patients with vascular liver diseases.
- Conditions
- Vascular Liver Disease, Portal Vein Thrombosis, Budd-Chiari Syndrome, Non-Cirrhotic Portal Hypertension
- Trial name
- VALID (NCT03541057)
- Where
- Austria
- Volunteers
- 200 people
- Sponsor
- Medical University of Vienna
Rendu Osler Disease
Calcium-phosphate Complications Induced by IV Iron Supplementation in Patients With Rendu-Osler Disease
Hypophosphatemia induced by treatments with injectable iron is a frequent side effect already reported during marketing. Situations of osteomalacia secondary to these hypophosphatemias are rarer and reported in the form of case…
- Trial name
- OS-LERETRO (NCT05544669)
- Where
- France
- Volunteers
- 220 people
- Sponsor
- University Hospital, Strasbourg, France
Rendu Osler Disease, Telangiectasia, Hereditary Hemorrhagic
The ELLIPSE Study: A Phase-1 Study Evaluating the Tolerance of Bevacizumab Nasal Spray to Treat Epistaxis in Hereditary Hemorrhagic Telangiectasia
Antiangiogenic drugs, such as bevacizumab, are a new treatment strategy in Hereditary Hemorrhagic Telangiectasia (HHT). Its systemic administration in patients with HHT improves liver damage-related symptoms and epistaxis (cases…
- Trial name
- ELLIPSE (NCT01507480)
- Testing
- Bevacizumab
- Volunteers
- 42 people
- Sponsor
- Hospices Civils de Lyon
Osler-Rendu-Weber Disease, Osler-Rendu Disease
Screening Behavior in Adults With Hereditary Hemorrhagic Telangiectasia
This study will explore the factors that influence screening behaviors of adults diagnosed with hereditary hemorrhagic telangiectasia (HHT), an inherited condition in which blood vessel defects called arteriovenous malformations…
- Conditions
- Osler-Rendu-Weber Disease, Osler-Rendu Disease, Telangiectasia, Hereditary Hemorrhagic
- Trial name
- NCT00684879
- Where
- United States
- Volunteers
- 320 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
Osler Rendu Disease, Hereditary Hemorrhagic Telangiectasia
Evaluation of Obstetrical and Neonatal Complications in Hereditary Haemorrhagic Telangiectasia (HHT)
Hereditary Haemorrhagic Telangiectasia (HHT) is a rare inherited genetic disease of autosomal dominant inheritance with a prevalence of about 1/5000.
- Trial name
- CONCERTO (NCT03691142)
- Testing
- Questionnaire
- Where
- France
- Volunteers
- 207 people
- Sponsor
- Hospices Civils de Lyon
Telangiectasia, Hereditary Hemorrhagic, Osler-Rendu Disease
ATERO : A Randomised Study With Tranexamic Acid in Epistaxis of Rendu Osler Syndrome
Scientific Objectives Primary objective : Demonstrate that oral intake of tranexamic acid significantly reduces the risk of epistaxis occurrence, estimated by the average monthly duration of episodes of epistaxis.
- Trial name
- NCT00355108
- Testing
- tranexamic acid
- Where
- France
- Volunteers
- 170 people
- Sponsor
- Hospices Civils de Lyon